Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 141 publications
Integrated molecular analysis of NSCLC brain metastasis tissue and multimodal ctDNA reveals distinct signatures of patient outcomes.
Journal: medRxiv : the preprint server for health sciences
Published: July 17, 2026
Treatment of Non-Small Cell Lung Cancer: A Clinical Model for Solid Tumors.
Journal: Cancer journal (Sudbury, Mass.)
Published: June 01, 2026
Matched targeted therapy use after broad genomic profiling in advanced Non-Small cell lung cancer.
Journal: Journal of the National Cancer Institute
Published: April 23, 2026
Is There Any Dose of Benzodiazepines Safe for Delirium in the PICU? A Secondary Analysis of the PICU Up! Pilot Trial Dataset.
Journal: Critical care explorations
Published: March 31, 2026
Disparities in stereotactic radiosurgery receipt in patients with brain metastases from non-small cell lung cancer.
Journal: Journal of neuro-oncology
Published: March 22, 2026
Medical Management of Non-Small Cell Lung Cancer Brain Metastases in the Modern Era.
Journal: Cancer journal (Sudbury, Mass.)
Published: March 03, 2026
Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 26, 2026
Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD.
Journal: European journal of cancer (Oxford, England : 1990)
Published: February 20, 2026
Durvalumab plus etoposide-platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: February 13, 2026
Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC after progression on first-line osimertinib: ORCHARD.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: January 19, 2026
Genomic Profiling of Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer after Progression on First-line Osimertinib: Phase II ORCHARD Study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 12, 2025
Genomic Profiling of Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Post-Progression on First-Line Osimertinib: Phase II ORCHARD Study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 12, 2025
Last Updated: 09/26/2026